|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006118,
umls-concept:C0006826,
umls-concept:C0026882,
umls-concept:C0029246,
umls-concept:C0035168,
umls-concept:C0087111,
umls-concept:C0205618,
umls-concept:C0220901,
umls-concept:C0239307,
umls-concept:C0681890,
umls-concept:C0684224,
umls-concept:C1257890,
umls-concept:C1274040,
umls-concept:C1335110,
umls-concept:C1415876,
umls-concept:C1415877
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2010-3-2
|
|
pubmed:abstractText |
Recent studies have shown the prognostic significance of IDH1 mutations in glioma. It is yet unclear if IDH1 mutations are predictive for outcome to chemotherapy. We determined the effect of IDH1 mutations on progression-free survival and overall survival (OS), and its correlation with other clinical and molecular features in the prospective randomized European Organization for Research and Treatment of Cancer study 26951 on adjuvant procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea, and vincristine (PCV) in anaplastic oligodendroglioma.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/DNA Modification Methylases,
http://linkedlifedata.com/resource/pubmed/chemical/DNA Repair Enzymes,
http://linkedlifedata.com/resource/pubmed/chemical/IDH1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Isocitrate Dehydrogenase,
http://linkedlifedata.com/resource/pubmed/chemical/Lomustine,
http://linkedlifedata.com/resource/pubmed/chemical/MGMT protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Procarbazine,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine,
http://linkedlifedata.com/resource/pubmed/chemical/isocitrate dehydrogenase 2, human
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:BrandesAlba AAA,
pubmed-author:DinjensWinand N MWN,
pubmed-author:DubbinkHendrikus JHJ,
pubmed-author:FrenayMarcM,
pubmed-author:GorliaThierryT,
pubmed-author:IdbaihAhmedA,
pubmed-author:KrosJohan MJM,
pubmed-author:LacombeDenisD,
pubmed-author:MarieYannickY,
pubmed-author:SansonMarcM,
pubmed-author:TaphoornMartin J BMJ,
pubmed-author:TijssenCees CCC,
pubmed-author:WesselingPieterP,
pubmed-author:van MarionRonaldR,
pubmed-author:van den BentMartin JMJ
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1597-604
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:20160062-Adolescent,
pubmed-meshheading:20160062-Adult,
pubmed-meshheading:20160062-Aged,
pubmed-meshheading:20160062-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20160062-Brain Neoplasms,
pubmed-meshheading:20160062-Combined Modality Therapy,
pubmed-meshheading:20160062-DNA Modification Methylases,
pubmed-meshheading:20160062-DNA Repair Enzymes,
pubmed-meshheading:20160062-Disease-Free Survival,
pubmed-meshheading:20160062-Female,
pubmed-meshheading:20160062-Genes, erbB-1,
pubmed-meshheading:20160062-Humans,
pubmed-meshheading:20160062-In Situ Hybridization, Fluorescence,
pubmed-meshheading:20160062-Isocitrate Dehydrogenase,
pubmed-meshheading:20160062-Kaplan-Meier Estimate,
pubmed-meshheading:20160062-Lomustine,
pubmed-meshheading:20160062-Male,
pubmed-meshheading:20160062-Middle Aged,
pubmed-meshheading:20160062-Mutation,
pubmed-meshheading:20160062-Oligodendroglioma,
pubmed-meshheading:20160062-Polymerase Chain Reaction,
pubmed-meshheading:20160062-Procarbazine,
pubmed-meshheading:20160062-Prognosis,
pubmed-meshheading:20160062-Promoter Regions, Genetic,
pubmed-meshheading:20160062-Radiotherapy,
pubmed-meshheading:20160062-Treatment Outcome,
pubmed-meshheading:20160062-Tumor Suppressor Proteins,
pubmed-meshheading:20160062-Vincristine,
pubmed-meshheading:20160062-Young Adult
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
|
|
pubmed:affiliation |
Dept Neuro-Oncology and Pathology, Daniel den Hoed Cancer Center and Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands. m.vandenbent@erasmusmc.nl
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase III,
Research Support, N.I.H., Extramural
|
